One nonprofit hospital is aggressively pursuing the poor for medical debts

Methodist University Hospital, based in Memphis, Tennessee, is a nonprofit hospital operator with its own collections agency that ruthlessly pummels low-income patients over unpaid medical bills by taking them to court, according to a sort by ProPublica. The act of taking patients to court for bills is not unheard of, but Methodist does it a higher rate than its peers, especially for a nonprofit.

The impact to patients when they are taken to court can be severe, as their bills often pile up with rising interest and collection fees from the hospital. For Carrie Barrett, a low-income worker in Memphis, a 2007 trip to the emergency room at the hospital left her with more than $12,000 in medical bills. Today, after being aggressively pursued by Methodist, she owes roughly $33,000 after interest and court fees and has seen her wages garnished by the hospital as a result of its collections process.

The hospital has sued thousands of patients over the years, all while claiming a tax-free status as a nonprofit operator, promising to provide a significant community benefit where it operates. Even Methodist’s own employees aren’t exempt from its practice of suing patients for medical debt.

By comparison, some nonprofit hospitals don’t sue patients at all.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.